Denver-based Intero Biosystems won the TechCrunch Disrupt 2026 Startup Battlefield, earning a $100,000 prize for its GastroScreen technology. The company uses lab-grown intestinal organoids to help pharmaceutical firms test drugs for safety before human trials. This highlights the growing investor focus on biotech solutions designed to reduce research costs and reliance on traditional animal testing.
The TechCrunch Disrupt 2026 Startup Battlefield in San Francisco has concluded with Intero Biosystems, a biotech startup based in Denver, taking the top prize. The company, which originated as a spin-out from the University of Michigan, was awarded $100,000 in non-dilutive capital and the Startup Battlefield Cup. The startup was chosen by a panel of venture capital judges from firms including Inspired Capital, Goodwater Capital, and M13, who evaluated 20 finalists for their potential to disrupt established industries through deep tech.
Intero Biosystems specializes in creating lab-grown human intestinal organoids, which are tiny tissues measuring about 1mm in size. These organoids are designed to replicate the actual functions of the human gut. The company markets this technology as GastroScreen, a tool that pharmaceutical and chemical companies can use to assess how drugs or compounds affect the body before moving into expensive and risky human clinical trials. By providing a more accurate simulation of human biology, this technology aims to help companies identify potential drug failures earlier in the development process.
For the pharmaceutical and biotech sectors, the cost of drug discovery remains a major financial challenge. Technologies that can improve the success rate of pre-clinical testing or reduce the time needed to bring a drug to market are becoming increasingly valuable. While traditional methods often rely on animal testing or simpler cellular models, organoid technology is gaining traction as a way to provide more reliable human-relevant data, which can reduce the costs and time spent on clinical research. This sector focus is likely why the startup received attention from venture capital investors looking for high-utility biotech innovation.
The competition also highlighted the broader interest in diverse deep-tech solutions. The runner-up, an Australian firm called Apate, focuses on using AI-driven agents to combat digital fraud. The success of both Intero Biosystems and Apate reflects a trend where venture funding is increasingly shifting toward technology that solves specific, high-stakes operational problems—whether that is lowering R&D costs in drug development or automating defenses against cyber threats.
Investors in the biotech space often watch companies like Intero Biosystems for their ability to scale manufacturing and secure partnerships with large pharmaceutical firms. The next phase for the company will likely involve scaling the production of its GastroScreen organoids and expanding its client base. The long-term value for shareholders and stakeholders in this field will depend on how successfully these companies can integrate their technology into the standard workflows of global drug development and chemical safety testing.